The drug makers Bioequivalence Center at Taloja successfully completed UK drug regulators inspection.
Sales decline 1.15% to Rs 239.05 crore
Sales rise 49.20% to Rs 31.51 crore
Sales rise 11.91% to Rs 441.43 crore
Sales rise 11.91% to Rs 441.43 crore
Sales rise 88.13% to Rs 215.92 crore
Sales rise 126.11% to Rs 7.10 crore
Sales decline 64.72% to Rs 11.59 crore
Sales rise 69.15% to Rs 156.80 crore
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
